MOR Morphosys 6-K2021MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
13 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
MOR 6-K Filings
- 26 Jan 21 MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
- 13 Jan 21 MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
- 12 Jan 21 MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
- 7 Jan 21 MorphoSys Appoints Sung Lee as Chief Financial Officer
- 5 Jan 21 MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…